XTRA:EVKChemicals
Is Evonik (XTRA:EVK) Quietly Reframing Its CDMO Strategy With The Tippecanoe Automation Upgrade?
In July 2026, Evonik announced a US$100 million, five-year investment to modernize large reactors and other core systems at its Tippecanoe Labs site in Lafayette, Indiana, reinforcing the facility’s role in supplying complex small-molecule drug substances for U.S.-based CDMO customers.
The upgrade focuses on Next Generation Technologies and greater automation, aiming to support complex molecule manufacturing, enhance energy-efficient processes, and reinforce resilient regional drug substance...